{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:07:51Z","timestamp":1762542471936},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reverse transcriptase (RT) mutations contribute to hepatitis B virus resistance during antiviral therapy with nucleos(t)ide analogs. However, the composition of the RT quasispecies and their interactions during antiviral treatment have not yet been thoroughly defined. In this report, 10 patients from each of 3 different virological response groups, i.e., complete virological response, partial virological response and virological breakthrough, were selected from a multicenter trial of Telbivudine treatment. Variations in the drug resistance-related critical RT regions in 107 serial serum samples from the 30 patients were examined by ultra-deep sequencing. A total of 496,577 sequence reads were obtained, with an average sequencing coverage of 4,641X per sample. The phylogenies of the quasispecies revealed the independent origins of two critical quasispecies, i.e., the rtA181T and rtM204I mutants. Data analyses and theoretical modeling showed a cooperative-competitive interplay among the quasispecies. In particular, rtM204I mutants compete against other quasispecies, which eventually leads to virological breakthrough. However, in the absence of rtM204I mutants, synergistic growth of the drug-resistant rtA181T mutants with the wild-type quasispecies could drive the composition of the viral population into a state of partial virological response. Furthermore, we demonstrated that the frequency of drug-resistant mutations in the early phase of treatment is important for predicting the virological response to antiviral therapy.<\/jats:p>","DOI":"10.1038\/srep17123","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T11:38:48Z","timestamp":1448365128000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy"],"prefix":"10.1038","volume":"5","author":[{"given":"Bin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yungang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weirong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,24]]},"reference":[{"key":"BFsrep17123_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4254\/wjh.v4.i3.74","volume":"4","author":"E Franco","year":"2012","unstructured":"Franco, E. et al. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol 4, 74\u201380 (2012).","journal-title":"World J Hepatol"},{"key":"BFsrep17123_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1053\/j.gastro.2012.01.044","volume":"142","author":"SJ Scaglione","year":"2012","unstructured":"Scaglione, S. J. & Lok, A. S. Effectiveness of hepatitis B treatment in clinical practice. GASTROENTEROLOGY 142, 1360\u20131368 (2012).","journal-title":"GASTROENTEROLOGY"},{"key":"BFsrep17123_CR3","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J HEPATOL57, 167\u2013185 (2012).","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"BFsrep17123_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok, A. S. & McMahon, B. J. Chronic hepatitis B: update 2009. HEPATOLOGY 50, 661\u2013662 (2009).","journal-title":"HEPATOLOGY"},{"key":"BFsrep17123_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"Y Liaw","year":"2012","unstructured":"Liaw, Y. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. HEPATOL INT 6, 531\u2013561 (2012).","journal-title":"HEPATOL INT"},{"key":"BFsrep17123_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cld.2010.05.004","volume":"14","author":"S Locarnini","year":"2010","unstructured":"Locarnini, S. & Bowden, S. Drug resistance in antiviral therapy. CLIN LIVER DIS 14, 439\u2013459 (2010).","journal-title":"CLIN LIVER DIS"},{"key":"BFsrep17123_CR7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","volume":"137","author":"F Zoulim","year":"2009","unstructured":"Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. GASTROENTEROLOGY 137, 1593\u20131608 (2009).","journal-title":"GASTROENTEROLOGY"},{"key":"BFsrep17123_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature04388","volume":"439","author":"M Vignuzzi","year":"2006","unstructured":"Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. NATURE 439, 344\u2013348 (2006).","journal-title":"NATURE"},{"key":"BFsrep17123_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1073\/pnas.0909787107","volume":"107","author":"S Ojosnegros","year":"2010","unstructured":"Ojosnegros, S. et al. Competition-colonization dynamics in an RNA virus. Proc Natl Acad Sci USA 107, 2108\u20132112 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep17123_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s11538-010-9596-2","volume":"73","author":"E Delgado-Eckert","year":"2011","unstructured":"Delgado-Eckert, E., Ojosnegros, S. & Beerenwinkel, N. The evolution of virulence in RNA viruses under a competition-colonization trade-off. Bull Math Biol 73, 1881\u20131908 (2011).","journal-title":"Bull Math Biol"},{"key":"BFsrep17123_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4161\/cib.3.4.11658","volume":"3","author":"S Ojosnegros","year":"2010","unstructured":"Ojosnegros, S., Beerenwinkel, N. & Domingo, E. Competition-colonization dynamics: An ecology approach to quasispecies dynamics and virulence evolution in RNA viruses. Commun Integr Biol 3, 333\u2013336 (2010).","journal-title":"Commun Integr Biol"},{"key":"BFsrep17123_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","volume":"48","author":"S Villet","year":"2008","unstructured":"Villet, S. et al. Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure. J HEPATOL 48, 747\u2013755 (2008).","journal-title":"J HEPATOL"},{"key":"BFsrep17123_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/hep.22295","volume":"48","author":"N Warner","year":"2008","unstructured":"Warner, N. & Locarnini, S. The antiviral drug selected hepatitis B virus rtA181T\/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. HEPATOLOGY 48, 88\u201398 (2008).","journal-title":"HEPATOLOGY"},{"key":"BFsrep17123_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3851\/IMP1552","volume":"15","author":"CT Yeh","year":"2010","unstructured":"Yeh, C. T. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide\/nucleoside analogue therapy. ANTIVIR THER 15, 471\u2013475 (2010).","journal-title":"ANTIVIR THER"},{"key":"BFsrep17123_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/bimj.4710380810","volume":"38","author":"J R\u00f6hmel","year":"1996","unstructured":"R\u00f6hmel, J. Precision Intervals for Estimates of the Difference in Success Rates for Binary Random Variables Based on the Permutation Principle. BIOMETRICAL J 38, 977\u2013993 (1996).","journal-title":"BIOMETRICAL J"},{"key":"BFsrep17123_CR16","doi-asserted-by":"crossref","unstructured":"Agresti, A. A survey of exact inference for contingency tables. STAT SCI, 7, 131\u2013153 (1992).","DOI":"10.1214\/ss\/1177011454"},{"key":"BFsrep17123_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature04388","volume":"439","author":"M Vignuzzi","year":"2006","unstructured":"Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. NATURE 439, 344\u2013348 (2006).","journal-title":"NATURE"},{"key":"BFsrep17123_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/scientificamerican0793-42","volume":"269","author":"M Eigen","year":"1993","unstructured":"Eigen, M. Viral quasispecies. SCI AM 269, 42\u201349 (1993).","journal-title":"SCI AM"},{"key":"BFsrep17123_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.dld.2011.07.002","volume":"43","author":"V Svicher","year":"2011","unstructured":"Svicher, V. et al. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis 43, 975\u2013983 (2011).","journal-title":"Dig Liver Dis"},{"key":"BFsrep17123_CR20","doi-asserted-by":"publisher","first-page":"e37874","DOI":"10.1371\/journal.pone.0037874","volume":"7","author":"F Rodriguez-Frias","year":"2012","unstructured":"Rodriguez-Frias, F. et al. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLOS ONE 7, e37874 (2012).","journal-title":"PLOS ONE"},{"key":"BFsrep17123_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jhep.2009.01.007","volume":"50","author":"P Lampertico","year":"2009","unstructured":"Lampertico, P. Partial virological response to nucleos(t)ide analogues in naive patients with chronic hepatitis B: From guidelines to field practice. J HEPATOL 50, 644\u2013647 (2009).","journal-title":"J HEPATOL"},{"key":"BFsrep17123_CR22","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.jhep.2011.04.006","volume":"55","author":"MN Hilleret","year":"2011","unstructured":"Hilleret, M. N., Larrat, S., Stanke-Labesque, F. & Leroy, V. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough? J HEPATOL 55, 1468\u20131469, 1469\u20131470 (2011).","journal-title":"J HEPATOL"},{"key":"BFsrep17123_CR23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/gut.2010.226225","volume":"60","author":"F Liu","year":"2011","unstructured":"Liu, F. et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. GUT 60, 1269\u20131277 (2011).","journal-title":"GUT"},{"key":"BFsrep17123_CR24","doi-asserted-by":"publisher","first-page":"e67606","DOI":"10.1371\/journal.pone.0067606","volume":"8","author":"J Ma","year":"2013","unstructured":"Ma, J. et al. Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLOS ONE 8, e67606 (2013).","journal-title":"PLOS ONE"},{"key":"BFsrep17123_CR25","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1111\/j.1365-2893.2011.01435.x","volume":"18","author":"S Mirandola","year":"2011","unstructured":"Mirandola, S. et al. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat 18, e212\u2013e216 (2011).","journal-title":"J Viral Hepat"},{"key":"BFsrep17123_CR26","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/j.1440-1746.2006.04768.x","volume":"21","author":"A Tsubota","year":"2006","unstructured":"Tsubota, A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naive patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 21, 1769\u20131771 (2006).","journal-title":"J Gastroenterol Hepatol"},{"key":"BFsrep17123_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/hep.26885","volume":"59","author":"J Sun","year":"2014","unstructured":"Sun, J. et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. HEPATOLOGY 59, 1283\u20131292 (2014).","journal-title":"HEPATOLOGY"},{"key":"BFsrep17123_CR28","doi-asserted-by":"crossref","unstructured":"Fan, R. et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. GUT 10.1136\/gutjnl-2014-308546. (2015).","DOI":"10.1136\/gutjnl-2014-308546"},{"key":"BFsrep17123_CR29","doi-asserted-by":"publisher","first-page":"e18708","DOI":"10.1371\/journal.pone.0018708","volume":"6","author":"B Zhou","year":"2011","unstructured":"Zhou, B. et al. Geographical and ethnic distribution of the HBV C\/D recombinant on the Qinghai-Tibet Plateau. PLOS ONE 6, e18708 (2011).","journal-title":"PLOS ONE"},{"key":"BFsrep17123_CR30","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1471-2105-13-S10-S6","volume":"13","author":"P Skums","year":"2012","unstructured":"Skums, P. et al. Efficient error correction for next-generation sequencing of viral amplicons. BMC BIOINFORMATICS 13, Suppl 10, S6 (2012).","journal-title":"BMC BIOINFORMATICS"},{"key":"BFsrep17123_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1471-2164-12-245","volume":"12","author":"A Gilles","year":"2011","unstructured":"Gilles, A. et al. Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC GENOMICS 12, 245 (2011).","journal-title":"BMC GENOMICS"},{"key":"BFsrep17123_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1086\/597808","volume":"199","author":"S Margeridon-Thermet","year":"2009","unstructured":"Margeridon-Thermet, S. et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J INFECT DIS 199, 1275\u20131285 (2009).","journal-title":"J INFECT DIS"},{"key":"BFsrep17123_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2105-5-113","volume":"5","author":"RC Edgar","year":"2004","unstructured":"Edgar, R. C. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC BIOINFORMATICS 5, 113 (2004).","journal-title":"BMC BIOINFORMATICS"},{"key":"BFsrep17123_CR34","unstructured":"Andrew, Rambaut (2014). Tree Figure Drawing Tool Version 1.4.2.Institute of Evolutionary Biology University of Edinburgh, UK. URL http:\/\/tree.bio.ed.ac.uk\/."},{"key":"BFsrep17123_CR35","doi-asserted-by":"crossref","unstructured":"Nowak, M. A. R. M. Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology. (Oxford university press, 2000).","DOI":"10.1093\/oso\/9780198504184.001.0001"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep17123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep17123","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep17123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T17:08:15Z","timestamp":1718212095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep17123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,22]]}},"alternative-id":["BFsrep17123"],"URL":"https:\/\/doi.org\/10.1038\/srep17123","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]},"assertion":[{"value":"6 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17123"}}